Device submissions for combination products: a data-driven perspective

By Ola Oyinloye2024-04-03T12:00:00

The rapid increase in novel therapies and innovative drug delivery methods particularly in the context of combination product regulatory submissions, requires the management of a significant amount of data between sponsors and regulators. Challenges arise when there is a lack of robust data management, and these challenges suggest a need to develop data-driven approaches for successful submissions and reviews. This article explores how data-driven approaches impact device submissions for combination products, highlighting challenges and opportunities that can be leveraged in the evolving regulatory landscape.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

1. REGISTER FOR FREE

Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

Create your own library to save your favourite content.

Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

3. JOIN TOPRA

Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member